Join
Live feed
·
PRReleasevia Quantisnow
Regulus Therapeutics Inc. logo

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ByQuantisnow·Wall Street's wire, on your screen.
RGLS· Regulus Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RGLS (Regulus Therapeutics Inc.) and more on Quantisnow.